ImmuneRegen BioSciences(R) Announces Strategic Partnership With Azopharma Product Development Group, Inc.
23 Setembro 2009 - 9:00AM
Marketwired
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR
BioSciences Holdings, Inc. (OTCBB: IRBS), today announced the
execution of a Letter of Intent to enter a Strategic Partnership
Agreement with Azopharma Product Development Group, Inc. Under the
agreement, Azopharma will perform research services to further
develop ImmuneRegen's lead drug candidate Homspera®.
Under the terms of this non-binding Letter of Intent, Azopharma
will provide full development services to ImmuneRegen, which
include drug manufacturing, formulation development, and
pre-clinical services including IND-enabling toxicology and safety
pharmacology studies. Azopharma is a leading Contract Research
Organization based in North America which is unique in being able
to provide total product development services for the
pharmaceutical, biotechnology, and medical device industries.
Additionally, Azopharma scientists have experience in the
development of inhaled drugs and medical devices, which is of
particular importance to ImmuneRegen.
Phil Meeks, CEO of Azopharma Product Development Group,
commented, "The potential benefits to humankind of ImmuneRegen's
lead compound has compelled Azopharma to undertake this strategic
partnership. We are excited to undertake the development activities
that will enable pre-clinical and clinical evaluation."
The agreement, which is subject to, among other things, the
completion of work scope and budget by both parties and the
negotiation and signing of a definitive agreement, is expected to
close within sixty days, with work to begin immediately upon
closing. In exchange for the services, ImmuneRegen intends to issue
a certain amount of common stock and common stock purchase warrants
to Azopharma, subject to the approval of the company's Board of
Directors.
"We believe this partnership will provide the most expedited
development of our lead candidate Homspera," said ImmuneRegen CEO
Michael Wilhelm. "We feel privileged to be entering this
relationship with Azopharma, given their extensive experience in
swiftly developing similar products."
About Azopharma Product Development Group, Inc.
Azopharma Product Development Group, The Total Product
Development Company™, is FDA registered, DEA approved and client
audited on a regular basis. In product development, it comes down
to the right people, their commitment and application of
experience. Partnering with Azopharma provides customers with the
confidence of assured success. We welcome visits to our South
Florida facilities as well as our other sites to conduct audits or
meet with our pharmaceutical scientists to outline a study that
meets your specific needs. For more information please visit
www.azopdogroup.com.
About ImmuneRegen BioSciences, Inc.
ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR
BioSciences Holdings, Inc. (OTCBB: IRBS), is a development-stage
biotechnology company focused on the research, development and
licensing of Homspera® and its derivatives. Homspera is an adult
stem cell active compound that in study results has been shown to
regenerate and strengthen the immune system and enhance wound
healing. Viprovex®, a derivative of Homspera, is being developed
for potential use against infectious diseases as a stand-alone or
combination therapy and as a vaccine adjuvant. To advance its
mission, the Scottsdale, Arizona based company has forged numerous
study partnerships with industry and academic leaders, including
Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory
Research Institute and Virion Systems. For more information, please
visit www.immuneregen.com.
Statements about ImmuneRegen's future expectations, including
statements about the potential use and scientific results for
ImmuneRegen's drug candidates, science and technology, and all
other statements in this press release other than historical facts,
are "forward-looking statements" within the meaning of Section 27A
of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934, and as that term is defined in the Private
Securities Litigation Reform Act of 1995. ImmuneRegen intends that
such forward-looking statements be subject to the safe harbors
created thereby. These future events may not occur as and when
expected, if at all, and, together with ImmuneRegen's business, are
subject to various risks and uncertainties. ImmuneRegen's actual
results could differ materially from expected results as a result
of a number of factors, including the uncertainties inherent in
research and development collaborations, pre-clinical and clinical
trials and product development programs (including, but not limited
to the fact that future results or research and development efforts
may prove less encouraging than current results or cause side
effects not observed in current pre-clinical trials), the
evaluation of potential opportunities, the level of corporate
expenditures and monies available for further studies, capital
market conditions, and others set forth in ImmuneRegen's periodic
report on Form 10-KSB for the year ended December 31, 2008 as filed
with the Securities and Exchange Commission. There are no
guarantees that any of ImmuneRegen's proposed products will prove
to be commercially successful. ImmuneRegen undertakes no duty to
update forward-looking statements.
Contact: Michael K. Wilhelm OR John Fermanis ImmuneRegen
BioSciences Inc. Phone: 480-922-3926 Email: Email Contact Email:
Email Contact
IR BioSciences (CE) (USOTC:IRBS)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
IR BioSciences (CE) (USOTC:IRBS)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024